UPDATE: JPMorgan Starts Xenon Pharmaceuticals (XENE) at Overweight, Adds to Analyst Focus List
Tweet Send to a Friend
(Updated - July 21, 2022 4:43 AM EDT)
JPMorgan analyst Tessa Romero initiates coverage on Xenon Pharmaceuticals (NASDAQ: XENE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Tessa Romero initiates coverage on Xenon Pharmaceuticals (NASDAQ: XENE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
